Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT07481994
Active, not recruiting Observational

Changes in Value-Based Assessment in Patients Undergoing Major Oncological Surgery

NCT07481994 · tracked via the Priya Life Science Czechia tracker
Phase
Observational
Started
2024-10-11
Last updated
2026-03-19

Condition(s) studied

SeniorOncologic Disease

Study summary

Introduction The study focuses on analyzing the level of awareness among oncological patients, their perception of their health status, and expectations regarding radical surgical intervention. It assesses changes in patients' attitudes toward their diagnosis, therapeutic options, and prognosis both preoperatively and postoperatively. The research involves a systematic collection of value-based medical history through structured interviews, enabling the identification of key factors influencing patient experience and decision-making processes in oncological treatment.

Eligibility

Sex
ALL
Min age
65 Years
Max age
100 Years
Healthy volunteers
Accepted
Inclusion Criteria: * • Age ≥ 65 years * Type of procedure: hemicolectomy, rectal amputation, cystectomy, extensive nephrectomy, malignant brain tumor * ASA classification III * No sensory impairment (blindness, deafness, deaf-muteness) * Patients had access to sensory aids (glasses) during assessment * No legal incapacity * Consent to participate in the study * Signed informed consent * Postoperative hospitalization in the ICU (anticipated during pre-anesthetic examination) Exclusion Criteria: * • Glasgow Coma Scale ≤ 14 * Somnolence, coma * Known psychiatric disorder * Effect of premedication, psychiatric or analgesic-sedative drugs during cognitive function assessment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Tomas Bata regional Hospital Zlín Czechia

More Tomas Bata Hospital, Czech Republic trials in Czechia

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07481994 on ClinicalTrials.gov ↗ ← All trials in Czechia